Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) CFO David Mountcastle sold 5,630 shares of the firm's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total value of $125,999.40. Following the sale, the chief financial officer now directly owns 179,676 shares in the company, valued at approximately $4,021,148.88. This trade represents a 3.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Privia Health Group Trading Down 0.5 %
PRVA stock opened at $22.24 on Friday. The firm has a market cap of $2.68 billion, a PE ratio of 222.42, a price-to-earnings-growth ratio of 3.47 and a beta of 0.85. The stock has a 50-day moving average price of $23.79 and a 200-day moving average price of $21.27. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $26.04.
Institutional Investors Weigh In On Privia Health Group
Several large investors have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. boosted its holdings in shares of Privia Health Group by 53.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after buying an additional 632 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after acquiring an additional 2,350 shares during the period. Financial Management Professionals Inc. bought a new position in Privia Health Group during the fourth quarter worth $51,000. Quarry LP grew its holdings in Privia Health Group by 344.6% in the third quarter. Quarry LP now owns 3,268 shares of the company's stock worth $60,000 after purchasing an additional 2,533 shares during the period. Finally, Neo Ivy Capital Management acquired a new stake in Privia Health Group in the third quarter worth $66,000. Institutional investors and hedge funds own 94.48% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have recently commented on PRVA. JMP Securities set a $29.00 price target on Privia Health Group in a research note on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and set a $30.00 target price on shares of Privia Health Group in a research report on Friday, March 21st. Macquarie began coverage on shares of Privia Health Group in a research report on Monday, December 16th. They issued an "outperform" rating and a $25.00 price target for the company. Canaccord Genuity Group lifted their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Piper Sandler boosted their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $26.67.
Get Our Latest Stock Analysis on PRVA
Privia Health Group Company Profile
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
